BPI Labs

• Pharmacy Profile Name: BPI Labs, LLC
• Website: bpi-labs.com
• Founded: 2012, as a subsidiary of Belcher Pharmaceuticals
• Address: Largo, Florida
• COO: Chandra Kasireddy
• Parent Company: Belcher Pharmaceuticals, LLC
• Pharmacy Type: FDA-registered drug manufacturer + 503B outsourcing facility
• GLP-1 Compounding: Semaglutide, Tirzepatide (with Vitamin B6)

About the Pharmacy

BPI Labs has grown into a premier manufacturer of high-quality injectable pharmaceuticals, headquartered in Largo, FL, dedicated to enhancing patient care by ensuring essential medicines are accessible and manufactured to the highest standards. It occupies a rare position in the compounded GLP-1 market — simultaneously one of the most technologically sophisticated facilities and one of the most scrutinized, thanks to its corporate parentage and a 2025 FDA inspection finding. Both aspects deserve equal weight from patients and prescribers evaluating the pharmacy.

GLP-1 Compounding

BPI Labs compounds both semaglutide and tirzepatide as sterile injectables. Its tirzepatide formulation includes Vitamin B6 (pyridoxine) — a well-established anti-nausea compound that also creates a formulation differing from commercially available branded tirzepatide, which has regulatory implications under the “not essentially a copy” provision that compounders use to continue operating post-shortage.

The manufacturing process sets BPI apart from most compounders. Inside ISO-grade barriers, humanless robotic technology performs every fill, cap, and inspection in complete isolation from external touchpoints, eliminating contamination risk and guaranteeing cGMP compliance at every step. Every batch undergoes rigorous in-house chemistry and microbiology testing, and BPI exceeds standard cGMP regulations with strict self-imposed guidelines, never relying on third-party Certificates of Analysis.

BPI has also taken an aggressive stance on the regulatory landscape: the company joined Empower Pharmacy in challenging Eli Lilly’s tirzepatide patent by filing a petition with the U.S. Patent Trial and Appeal Board, presenting prior art to support claims of the patent’s invalidity.

Type of Pharmacy

BPI Labs holds a genuinely unusual credential stack. BPI Labs is an FDA-registered drug manufacturer and 503B outsourcing facility — a wholly owned subsidiary of Belcher Pharmaceuticals, LLC. All compounded medications follow 21 CFR Part 210 and 211 (cGMP), the same regulatory framework as traditional pharmaceutical manufacturers. It is described by pharmacy industry sources as the only FDA-registered drug manufacturer with a 503B pharmacy producing GLP-1s — a distinction that places it under stricter federal manufacturing oversight than either 503A pharmacies or standard 503B outsourcing facilities.

Important background on parent company: BPI Labs is wholly owned by Belcher Pharmaceuticals. In 2020, two Belcher executives were convicted in a major healthcare fraud scheme involving kickbacks to physicians and repackaging over-the-counter products as prescription drugs. One executive, Mihir Taneja, pleaded guilty and was sentenced to 10 months in prison and ordered to pay nearly $21 million. BPI has stated publicly that neither Belcher nor BPI have ever received FDA Warning Letters, and that the fraud convictions relate to Belcher personnel, not to BPI’s manufacturing operations. Prospective partners should weigh this background alongside BPI’s technical credentials.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

States Licensed In

BPI Labs maintains licensing in 49 of 50 states, operating from its single facility in Largo, Florida. The near-universal licensing makes it accessible to virtually all telehealth platforms and clinics operating nationally.

Telehealth Providers They Work With

BPI Labs is a supplier pharmacy, not a consumer-facing operation. Known confirmed telehealth and platform partners include:

• Hims & Hers — Hims partnered with BPI Labs for its compounded semaglutide GLP-1 program, offering injections starting at $199/month
• Belle Health — listed as a BPI Labs partner on GLP Winner’s pharmacy comparison platform, with compounded semaglutide from $199/month
• GobyMeds — listed on GLP Winner as a BPI Labs-sourced platform at $169/month for compounded semaglutide

Pricing from Reviews

Pricing is set by partner telehealth platforms, not by BPI Labs directly. Based on known platform pricing for BPI Labs-sourced medications:

• Compounded semaglutide: from $169/month (GobyMeds) to $199/month (Hims & Hers, Belle Health)
• Pricing remains flat across dose levels on several partner platforms, consistent with the GLP-1 market norm for compounders using the “same price at every dose” model

Overall Reviews

BPI Labs does not have a consumer-facing Trustpilot or Google Business profile — it is a B2B manufacturer supplying clinics, hospitals, and telehealth platforms rather than direct-to-patient. Patient reviews of BPI-sourced medication appear within the review records of partner platforms, most prominently Hims & Hers.

The pharmacy’s technical infrastructure — robotic aseptic filling, in-house batch testing, FDA drug manufacturer registration — is cited positively across professional pharmacy and compounding industry commentary. A February 2025 FDA Form 483 found that compounded drug labels lacked mandatory information required under Section 503B, including the statement “Office Use Only,” affecting multiple sterile injectable batches including semaglutide and tirzepatide vials. BPI states its most recent 503B audit resulted in no 483 observations — suggesting this issue was addressed.

The Belcher Pharmaceuticals fraud history remains the most significant reputational concern and should be understood in full by any prescriber or platform evaluating BPI as a pharmacy partner.